Schmidinger, Manuela

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Escudier, B., Porta, C., Schmidinger, M., Rioux-Leclercq, N., Bex, A., Khoo, V., Grünwald, V., Gillessen, S., & Horwich, A. (2019) · Annals of Oncology

Renal cell carcinoma treatmentBladder and Urothelial Cancer Treatments

Cited by 1,151

Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor–Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial

Rini, B. I., Moslehi, J. J., Bonaca, M., Schmidinger, M., Albiges, L., Choueiri, T. K., Motzer, R. J., Atkins, M. B., Haanen, J., Mariani, M., et al. (2022) · Journal of Clinical Oncology

Renal cell carcinoma treatmentChemotherapy-induced cardiotoxicity and mitigation

Cited by 77

Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial

Grimm, M.-O., Esteban, E., Barthélémy, P., Schmidinger, M., Busch, J., Valderrama, B. P., Charnley, N., Schmitz, M., Schumacher, U., Leucht, K., et al. (2023) · The Lancet Oncology

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 37

Belzutifan (bel) plus lenvatinib (lenva) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti–PD-(L)1 therapy: Open-label phase 3 LITESPARK-011 study.

Motzer, R. J., Park, S. H., McDermott, R. S., Porta, C., Heng, D. Y. C., Burotto, M., Iacovelli, R., Verzoni, E., Cutuli, H., Haanen, J., et al. (2026) · Journal of Clinical Oncology

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 9